RxDoctor Payments Data

Nicole Prentice-Gaytan, DO

Internal Medicine · Colorado Springs, CONPI 1295182236

Payments from drug & device makers

$3,837in general payments, 2019–2025

Across 40 payments — averaging $95.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Cardiovascular Systems Inc.$292
  • Boston Scientific$286
  • United Therapeutics Corporation$124
  • Philips North America LLC$101
  • Merck$96
  • plus $252 from 7 others

What the payments were for

  • Grants$56315%
  • Travel & lodging$1,12429%
  • Food & beverage$2,03953%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,837 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$90,511
Medicare patients
655
Services billed
1,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$176,007
JardianceEmpagliflozin118$126,096
EntrestoSacubitril/Valsartan50$65,033
FarxigaDapagliflozin Propanediol35$30,819
XareltoRivaroxaban21$24,792
Repatha SureclickEvolocumab14$22,015
Praluent PenAlirocumab13$8,985
Metoprolol Succinate264$2,856
Bumetanide31$2,575
PradaxaDabigatran Etexilate Mesylate12$2,393
Rosuvastatin Calcium141$1,734
Potassium Chloride78$1,625
Atorvastatin Calcium145$1,409
Losartan Potassium151$1,326
Carvedilol141$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$176,007154 claims
AstraZenecaFarxiga$12$30,81935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →